Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 145,445 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Anxiety, Stress
Interventions: Alcohol Alternative Herbal Tincture (Test Product), Placebo; Dietary Supplement
Lead sponsor: Apothekary; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Randomized, Phase 2, Epcoritamab, Watch & Wait, Untreated, Tumor Burden, Follicular Lymphoma
Interventions: Epcoritamab, Observation; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more

Conditions: Foot Ulcer, Diabetes Mellitus, Wound
Interventions: Wound debridement; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: SKI-606 (Bosutinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Duarte, California • Santa Monica, California • Tampa, Florida + 1 more

Conditions: COVID-19
Interventions: Vielight RX Plus; Device
Lead sponsor: Vielight Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Amyloidosis
Interventions: SandboxAQ CardiAQ Magnetocardiography; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Renal Cell Carcinoma
Interventions: Nivolumab, Axitinib, Cabozantinib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Springdale, Arkansas • Louisville, Kentucky • St Louis, Missouri + 5 more

Conditions: Melanoma (Skin)
Interventions: cisplatin, sorafenib tosylate, tamoxifen citrate, adjuvant therapy; Drug · Procedure
Lead sponsor: San Diego Pacific Oncology & Hematology Associates; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Encinitas, California

Conditions: T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions: Ruxolitinib, Duvelisib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more

Conditions: Recession, Gingival, Surgical Procedure, Unspecified, Graft Complication, Wound Heal
Interventions: Surgical Blade, Mucotome, Diamond Bur, Er:YAG Laser; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more

Conditions: Methamphetamine Abuse, Methamphetamine Dependence, Substance Abuse
Interventions: Placebo, N-acetylcysteine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Anemia, Thalassemia
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Ascites
Interventions: Sodium restriction; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gastroparesis
Interventions: Enterra Therapy Gastric Stimulator; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Disease
Interventions: MP-470 + topotecan, MP-470 + docetaxel, MP-470 + erlotinib, MP-470 + paclitaxel/carboplatin, MP-470 + carboplatin/etoposide; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Scottsdale, Arizona • Santa Monica, California • San Antonio, Texas

Conditions: Pharyngitis
Interventions: placebo, flurbiprofen, acetaminophen 650mg; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Epilepsy; Seizure
Interventions: Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring, Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: PTSD
Interventions: RESCUE, Prolonged Exposure; Behavioral
Lead sponsor: Charleston Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 891 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Hepatocellular Carcinoma
Interventions: ThermoDox, Dummy infusion; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neural Systems, Psychopathology
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 20 Years to 50 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Interventions: Prescreening Assessments; Diagnostic Test
Lead sponsor: Ascidian Therapeutics, Inc; Industry
Eligibility: 5 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 5 more

Search by objective public record fields.

A Clinical Trial to Assess the Impact of an Alcohol Alternative Herbal Tincture on Signs of Stress Anxiety and Sleep Quality.

Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Diabetic Foot Ulcers Microbiome and Pathogen Identification

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

A Study Of MCG In Cardiac Amyloidosis

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Alternative Gingival De-Epithelialization Techniques

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NAC as a Potential Treatment for Methamphetamine Dependence

Bone Marrow for Hemoglobinopathy Research

Sodium Restriction in the Management of Cirrhotic Ascites

Enterra Therapy Gastric Stimulation System

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

Thalamus Seizure Detection With a Deep Brain Stimulator System

Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD

RAPID-RF: Remote Active Monitoring in Patients With Heart Failure

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

Psychological Mechanisms of Behavioral Dysregulation

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)